BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 17 April 2008. doi:10.1136/bjo.2007.126227
British Journal of Ophthalmology 2008;92:810-813
Copyright © 2008 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
bjo.2007.126227v1
92/6/810    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tammewar, A M
Right arrow Articles by Freeman, W R
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tammewar, A M
Right arrow Articles by Freeman, W R

ORIGINAL ARTICLES

Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections

A M Tammewar, L Cheng, O R Kayikcioglu, I A Falkenstein, I Kozak, M H Goldbaum, W R Freeman

1 Joan and Irwin Jacobs Retina Center at the Shiley Eye Center, UCSD Department of Ophthalmology, La Jolla, California, USA

Correspondence to:
Professor W R Freeman, Joan and Irwin Jacobs Retina Center, Shiley Eye Center, UCSD Department of Ophthalmology, La Jolla, CA 92037, USA; freeman{at}eyecenter.ucsd.edu

Aims: To compare the non-decanted (standard) 4 mg versus the decanted 20 mg intravitreal triamcinolone acetonide (IVTA) injections and to assess their effect on intraocular pressure (IOP).

Methods: We retrospectively reviewed the records of 92 consecutive eyes, which received an intravitreal injection of either dose of triamcinolone acetonide, at a single retina centre. The change in IOP (elevation of at least 5 mm Hg from baseline or above 21 mm Hg) was analysed with a multivariate logistic analysis. The mean follow-up period in both groups was 27 weeks. A subgroup analysis comparing vitrectomised to non-vitrectomised eyes in both groups was also performed.

Results: Of the 92 eyes, 46% (23 of 51) in the 4 mg group versus 30% (12 of 41) in the 20 mg group had an IOP >21 mm of Hg (p = 0.14) after a mean follow-up period of 27 weeks. The vitrectomised eyes (3 of 24) in the 20 mg group had a significantly lower rate of IVTA induced IOP elevation than the non-vitrectomised eyes (9 of 17) (p = 0.013). The IOP elevation occurred significantly earlier in the 4 mg group (vitrectomised eyes 27 (SD 43) days and non-vitrectomised eyes 61 (52) days) than in the 20 mg group (vitrectomised eyes 104 (56) days and non-vitrectomised eyes 119 (82) days), independent of the vitreous status (vitrectomised p = 0.05 and non-vitrectomised p = 0.04). The mean value of initial high IOP in the non-vitrectomised eyes was higher in the 4 mg group than in the corresponding 20 mg group (p = 0.048).

Conclusion: Decanted 20 mg IVTA may not pose a significantly greater risk of IOP elevation than the 4 mg non-decanted IVTA.


Funding: This research was supported in part by unrestricted retina research funds from Jacobs Retina Center, La Jolla, CA (WRF and LC). AMT has received a travel grant from Rameshwardasji Birla Smarak Kosh, Medical Research Center, Bombay Hospital Avenue, Mumbai, India.

Competing interests: None.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd.